Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Plant-based medicament for the treatment of liver disease

A technology of medicines and plants, applied in the field of plant medicines or dietary supplements, can solve the problem that there is no safe and effective combination of Western herbal medicines, Chinese herbal medicines, etc.

Inactive Publication Date: 2008-09-24
PHYNOVA LTD
View PDF7 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The prior art does not suggest combining Western herbal medicines with a limited number of Chinese herbal medicines, nor does it have any actual indication that such a combination would be safe and effective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Plant-based medicament for the treatment of liver disease
  • Plant-based medicament for the treatment of liver disease
  • Plant-based medicament for the treatment of liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0180] Preparation of botanical drugs from botanical drug substances

[0181] Standardized extracts of milk thistle (fruit), salvia miltiorrhiza (root), Schisandra chinensis (fruit), and Astragalus mongolica (root) were prepared separately using extraction methods specially designed for each herb to achieve the desired therapeutic potency of the extracts . The extracts were dried and the resulting dry powdered extracts were mixed in the following proportions (both the weight of the extract and the equivalent weight by weight of dry plant material are given).

[0182] (a) Milk thistle: 0.200g to 0.250g (equivalent to 12g to 15g of plant material),

[0183] (b) Astragalus mongolica: 0.585g to 1.95g (equivalent to 9g to 30g of plant material),

[0184] (c) Danshen: 0.225g to 0.375g (equivalent to 9g to 15g of plant material), and

[0185] (d) Schisandra: 0.150 g to 0.600 g (equivalent to 1.5 g to 6 g of plant material).

Embodiment 2

[0187] Formulated as a suspension mixture

[0188] The spray-dried botanical drug substance of Example 1 was formulated into a suspension dosage form by mixing the spray-dried botanical drug substance with:

[0189] a) one or more gelling or thickening agents comprising at least one xanthum gum having a particle size distribution such that 100% by weight of the particles pass through a 60 mesh sieve, 95% by weight of the granules pass through an 80-mesh sieve and 70% by weight of the granules pass through a 200-mesh sieve;

[0190] b) one or more fillers; and

[0191] c) One or more humectants and / or surfactants.

[0192] The resulting formulation, known as PYN17 Suspension Powder Mix, contains the following ingredients:

[0193] Composition: per capsule

[0194] Active ingredient:

[0195] Milk thistle fruit dry extract: 0.200g

[0196] Salvia root dry extract: 0.225g

[0197] Schisandra fruit dry extract 0.400g

[0198] Astragalus root dry extract: 0.585g

[019...

Embodiment 3

[0208] Activity of PYN17 Suspension Powder Mixture

[0209] One sachet suspension powder was resuspended in 2.5ml of water and further diluted 1 / 7. The incompletely dissolved suspension was filtered and the soluble fraction was tested.

[0210] 10 μl of the solution was tested at a concentration of 1 / 70 in 100 μl of cell culture. Concentrations of 1 / 350 and 1 / 1750 were also used to determine toxicity.

[0211] To test toxicity, cells were incubated with Replicon cells for 72 hours and tritiated thymidine was added 18 hours before harvesting the cells.

[0212] result:

[0213] Tritiated thymidine incorporation.

[0214] to dilute

PYN-17

1st hole

cpm

2nd hole

cpm

3rd hole

cpm

4th hole

cpm

5th hole

cpm

average

cpm

1 / 70

18

24

65

51

77

1 / 350

41010

32432

34719

30311

32371

34169

1 / 1750

36210

28315

32424 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to further medical uses for a botanical drug or dietary supplement consisting essentially of four botanical drug substances, optionally formulated with excipients. The botanical raw materials, botanical drug substances or botanical ingredients used are from a species of each of the genera: (a) Silybum; (b) Astragalus or Hedysarum; (c) Salvia; and (d) Schisandra.

Description

[0001] technical field of invention [0002] The present invention relates to botanical medicines or dietary supplements for the treatment of patients with liver disease HCV-related liver disease, HBV-related liver disease or liver disease caused by drug abuse, alcohol abuse or diabetes. More specifically, the present invention relates to the use of a botanical drug consisting essentially of four botanical drug substances, optionally formulated together with excipients. [0003] In particular, the present invention relates to the discovery that the claimed composition exhibited activity in clinical trials, suggesting that in addition to the antiviral In addition to, or as an alternative to, the composition additionally shows promise as: [0004] 1. Candidates for use as adjuvant therapy to interferon and ribavirin (or other immunomodulator / antiviral drug combinations); [0005] 2. Candidates for the treatment of patients who do not respond to treatment with interferon and riba...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/28A61K36/481A61K36/48A61K36/53A61K36/79A61P31/20A61P1/16A61K36/537
CPCA61K36/48A61K36/537A61K36/481A61K36/28A61K36/79A61P1/16A61P29/00A61P3/00A61P31/14A61P31/20A61P35/00A61K2300/00
Inventor 钟守明余虹雯
Owner PHYNOVA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com